Rademikibart vs SSGJ-611

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline

Rademikibart

Developed by Connect Biopharma and partners

Phase 3 in Atopic Dermatitismonoclonal antibody
Partial signal

NCT05017480 · Phase 2 · completed

SEASIDE CHINA was a randomized, double-blind, placebo-controlled Phase 2 trial in 330 Chinese adults and adolescents with moderate to severe atopic dermatitis, randomized 2:1 to rademikibart or placebo for 16 weeks. The primary endpoint was vIGA 0 or 1 with a reduction of at least 2 points at week 16. It was reached by 29.0% on rademikibart vs 5.9% on placebo (P<0.001), so the primary was met. Source: the SEASIDE CHINA paper (Br J Dermatol 2026).

Reported efficacy

Investigator Global Assessment (IGA) (0-1) (Baseline to Week16): vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026). (met)

Result source: NCT05017480

SSGJ-611

Developed by Sunshine Guojian Pharmaceutical and partners

Phase 3 in Atopic Dermatitismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT07767253 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointRademikibartSSGJ-611
EASI-7558.6% vs 22.6%+36 vs placebo300mg Q2W · wk 16 · n 219NCT05017480—Not posted · NCT06173284
IGA 0/1 with 2-point improvement—Not posted · NCT06477835—Not posted · NCT06173284
EASI-9033.4% vs 6.4%+27 vs placebo300mg Q2W · wk 16 · n 219NCT05017480—Not posted · NCT06173284
EASI, % change-57.6% vs -39.7%−17.9 vs placebo150 Q2W · wk 16 · n 57NCT04444752
2 other results
  • -63.0% vs -39.7% 300 Q2W · wk 16 · n 57 · Phase 2 · primary NCT04444752
  • -63.5% vs -39.7% 300 Q4W · wk 16 · n 56 · Phase 2 · primary NCT04444752
—Not posted · NCT06173284

EASI-75

Rademikibart
58.6% vs 22.6%+36 vs placebo300mg Q2W · wk 16 · n 219NCT05017480
SSGJ-611
—Not posted · NCT06173284

IGA 0/1 with 2-point improvement

Rademikibart
—Not posted · NCT06477835
SSGJ-611
—Not posted · NCT06173284

EASI-90

Rademikibart
33.4% vs 6.4%+27 vs placebo300mg Q2W · wk 16 · n 219NCT05017480
SSGJ-611
—Not posted · NCT06173284

EASI, % change

Rademikibart
-57.6% vs -39.7%−17.9 vs placebo150 Q2W · wk 16 · n 57NCT04444752
2 other results
  • -63.0% vs -39.7% 300 Q2W · wk 16 · n 57 · Phase 2 · primary NCT04444752
  • -63.5% vs -39.7% 300 Q4W · wk 16 · n 56 · Phase 2 · primary NCT04444752
SSGJ-611
—Not posted · NCT06173284
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SSGJ-611: no structured comparison results are available for Atopic Dermatitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Rademikibart: 4 of 4 rows · SSGJ-611: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRademikibart
Dropout rate
4.6%300mg Q2Wa
NCT05017480 · Phase 2
show 6 more results
—300mg Q2W
NCT05017480 · Phase 2
—300mg Q4W
NCT05017480 · Phase 2
—300mg Q2W
NCT05017480 · Phase 2
19.3%150 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
21.1%300 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
10.7%300 Q4W
NCT04444752 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.5%300mg Q2Wa
NCT05017480 · Phase 2
show 6 more results
—300mg Q2W
NCT05017480 · Phase 2
—300mg Q4W
NCT05017480 · Phase 2
—300mg Q2W
NCT05017480 · Phase 2
1.8%150 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
0%300 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
0%300 Q4W
NCT04444752 · Phase 2 · registry result, not featured evidence
Serious AEs
0.5%300mg Q2Wa
NCT05017480 · Phase 2
show 6 more results
0.9%300mg Q2W
NCT05017480 · Phase 2
2.7%300mg Q4W
NCT05017480 · Phase 2
7.1%300mg Q2W
NCT05017480 · Phase 2
1.8%150 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
0%300 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
3.6%300 Q4W
NCT04444752 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
300mg Q2Wa
atopic dermatitis 10.5% (placebo 17.1%)
hyperlipidaemia 10.5% (placebo 5.4%)
hyperuricemia 9.6% (placebo 4.5%)
NCT05017480 · Phase 2
show 6 more results
300mg Q2W
covid-19 33.6% (placebo 0%)
atopic dermatitis 12.4% (placebo 17.1%)
upper respiratory infection 10.6% (placebo 6.3%)
NCT05017480 · Phase 2
300mg Q4W
covid-19 30.4% (placebo 0%)
atopic dermatitis 24.1% (placebo 17.1%)
upper respiratory infection 10.7% (placebo 6.3%)
NCT05017480 · Phase 2
300mg Q2W
covid-19 24.7% (placebo 0%)
upper respiratory infection 17.6% (placebo 6.3%)
atopic dermatitis 16.5% (placebo 17.1%)
NCT05017480 · Phase 2
150 Q2W
dermatitis atopic 12.3% (placebo 14.3%)
covid-19 7% (placebo 7.1%)
urinary tract infection 7% (placebo 1.8%)
NCT04444752 · Phase 2 · registry result, not featured evidence
300 Q2W
dermatitis atopic 8.8% (placebo 14.3%)
nasopharyngitis 5.3% (placebo 7.1%)
conjunctivitis 3.5% (placebo 0%)
NCT04444752 · Phase 2 · registry result, not featured evidence
300 Q4W
dermatitis atopic 25% (placebo 14.3%)
headache 7.1% (placebo 0%)
nausea 5.4% (placebo 0%)
NCT04444752 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Rademikibart

IGA 0/1 29% (n=219) vs 5.9% (n=111) placebo @ 16wk300mg Q2W
responder rate · % of participants
NCT05017480 · Phase 2
show 3 more results
15.8% (n=57) vs 8.9% (n=56) placebo @ 16wk*150 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
28.1% (n=57) vs 8.9% (n=56) placebo @ 16wk*300 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence · converted to % from 16 Participants as posted
19.6% (n=56) vs 8.9% (n=56) placebo @ 16wk*300 Q4W
NCT04444752 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
EASI-75 58.6% (n=219) vs 22.6% (n=111) placebo @ 16wk300mg Q2W
responder rate · % of participants
NCT05017480 · Phase 2
PP-NRS4 36.3% (n=216) vs 10.5% (n=110) placebo @ 16wk300mg Q2W
responder rate · % of participants
NCT05017480 · Phase 2
Itch NRS 3 50% (n=218) vs 20.3% (n=111) placebo @ 16wk300mg Q2W
responder rate · % of participants
NCT05017480 · Phase 2
PP-NRS -2.95 vs -0.99 placebo score @ 16wk300mg Q2W
absolute change · score
NCT05017480 · Phase 2
EASI-90 33.4% (n=219) vs 6.4% (n=111) placebo @ 16wk300mg Q2W
responder rate · % of participants
NCT05017480 · Phase 2
PP-NRS -40% (n=219) vs -13.5% (n=111) placebo @ 16wk300mg Q2W
percent change · % of baseline
NCT05017480 · Phase 2
EASI -57.56% (n=57) vs -39.67% (n=56) placebo @ 16wk150 Q2W
percent change · % of baseline
NCT04444752 · Phase 2 · registry result, not featured evidence · converted to % from 57.56 percent reduction from Baseline as posted
show 2 more results
-63.03% (n=57) vs -39.67% (n=56) placebo @ 16wk*300 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence · converted to % from 63.03 percent reduction from Baseline as posted
-63.5% (n=56) vs -39.67% (n=56) placebo @ 16wk*300 Q4W
NCT04444752 · Phase 2 · registry result, not featured evidence · converted to % from 63.5 percent reduction from Baseline as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rademikibart's landscape · SSGJ-611's landscape